Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Functional cure reported in CLL

Matthew S. Davids

Blood (2023) 142 (21): 1761–1763.

https://doi.org/10.1182/blood.2023021954

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

John N. Allan, Adam S Kittai, Dan James, Helen Ridge, Miguel Miranda, Alan Yong, Fady Fam, Jack Roos, Vikram Shetty, Matthew S. Davids, Alan Skarbnik

Blood (2023) 142 (Supplement 1): 6563.

https://doi.org/10.1182/blood-2023-178698

Published: 2023

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Matthew S Davids, Yesid Alvarado Valero, Catherine Diefenbach, Daniel N. Egan, Shira N. Dinner, Monzr M. Al Malki, Kebede Begna, Avyakta Kallam, Sameem Abedin, Rachel Cook, Nathalie Javidi-Sharifi, Edward Dominguez, Lu Miao, Richard G Ghalie, Alexey Danilov

Blood (2023) 142 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2023-179577

Published: 2023

Journal Articles

Combination of Ibrutinib with CD19 Chimeric Antigen Receptor (CAR) T Cells Suggests Greater Contribution to CAR T-Cell Efficacy Than Other Approved BTK Inhibitors in the Preclinical Setting

Vicki Plaks, Vidusha Cyril, Peter A Riedell, Qianqian Zhao, Jason Hall, Joel Tan, Diala Harb, Matthew S Davids

Blood (2023) 142 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2023-181805

Published: 2023

Journal Articles

Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors

Aishath Naeem, Liang Li, Filippo Utro, Justin Cha, Junko Tsuji, Stacey M Fernandes, Roberta Santos Azevedo, Francesca Morelli, Zunqiu Wang, Samantha J. Shupe, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P Danysh, Alexandria Kluge, Matthew S Davids, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2023-186052

Published: 2023

Journal Articles

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Kiyomi Mashima, Mariia Mikhaleva, Stacey M Fernandes, Samantha J. Shupe, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6507.

https://doi.org/10.1182/blood-2023-187406

Published: 2023

Journal Articles

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Mariia Mikhaleva, Svitlana Tyekucheva, Kiyomi Mashima, Stacey M Fernandes, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2023-173738

Published: 2023

Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Blood (2023) 142 (Supplement 1): 1908.

https://doi.org/10.1182/blood-2023-179198

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 497.

https://doi.org/10.1182/blood-2023-182114

Published: 2023

Journal Articles

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood (2023) 142 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2023-173992

Published: 2023

Journal Articles

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Kevin H. Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric M. Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S Davids

Blood (2023) 142 (Supplement 1): 4652.

https://doi.org/10.1182/blood-2023-180793

Published: 2023

Journal Articles

Repurposing GSK3B Small Molecule Inhibitors for Refractory Lymphoid Malignancies

Blood (2023) 142 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2023-190522

Published: 2023

Journal Articles

Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies

Blood (2023) 142 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2023-174384

Published: 2023

Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6536.

https://doi.org/10.1182/blood-2023-178727

Published: 2023

Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2023-173103

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Blood (2023) 142 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2023-182188

Published: 2023

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 108.

https://doi.org/10.1182/blood-2023-180858

Published: 2023

Journal Articles

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jennifer L Crombie, Austin I Kim, Nancy L. Bartlett, Robert A. Redd, Victoria Patterson, Celeste Carey, Sobana Balasubramanian, Oreofe O. Odejide, Reid W. Merryman, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, David C Fisher, Alex F. Herrera, Matthew S Davids, Margaret A. Shipp, Philippe Armand, Geoffrey P. Shouse

Blood (2023) 142 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2023-181067

Published: 2023

Journal Articles

Safety, Efficacy and T-Cell Predictive Biomarkers in a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey P. Shouse, Leslie L. Popplewell, Alex Muir, Tanya Siddiqi, Alex F. Herrera, Olga Danilova, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S Davids, Alexey Danilov

Blood (2023) 142 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2023-182559

Published: 2023

NARROW

Functional cure reported in CLL

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Combination of Ibrutinib with CD19 Chimeric Antigen Receptor (CAR) T Cells Suggests Greater Contribution to CAR T-Cell Efficacy Than Other Approved BTK Inhibitors in the Preclinical Setting

Understanding Resistance Mechanisms and Growth Kinetics of CLL Treated with Covalent and Non-Covalent BTK Inhibitors

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi)

Repurposing GSK3B Small Molecule Inhibitors for Refractory Lymphoid Malignancies

Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Safety, Efficacy and T-Cell Predictive Biomarkers in a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only